<?xml version='1.0' encoding='utf-8'?>
<document id="19856794"><sentence text="Pharmacokinetics characterization of liposomal amphotericin B: investigation of clearance process and drug interaction potential."><entity charOffset="47-61" id="DDI-PubMed.19856794.s1.e0" text="amphotericin B" /></sentence><sentence text="AmBisome, a liposomal formulation of amphotericin B (CAS 1397-89-3, L-AMB), shows different pharmacokinetics from the conventional formulation, amphotericin B deoxycholate (D-AMB)"><entity charOffset="37-51" id="DDI-PubMed.19856794.s2.e0" text="amphotericin B" /><entity charOffset="68-73" id="DDI-PubMed.19856794.s2.e1" text="L-AMB" /><entity charOffset="144-171" id="DDI-PubMed.19856794.s2.e2" text="amphotericin B deoxycholate" /><entity charOffset="173-178" id="DDI-PubMed.19856794.s2.e3" text="D-AMB" /><pair ddi="false" e1="DDI-PubMed.19856794.s2.e0" e2="DDI-PubMed.19856794.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19856794.s2.e0" e2="DDI-PubMed.19856794.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19856794.s2.e0" e2="DDI-PubMed.19856794.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19856794.s2.e0" e2="DDI-PubMed.19856794.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19856794.s2.e1" e2="DDI-PubMed.19856794.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19856794.s2.e1" e2="DDI-PubMed.19856794.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19856794.s2.e1" e2="DDI-PubMed.19856794.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19856794.s2.e2" e2="DDI-PubMed.19856794.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19856794.s2.e2" e2="DDI-PubMed.19856794.s2.e3" /></sentence><sentence text=" To characterize the clearance process of L-AMB, the form in which it exists in rat plasma, pharmacokinetics in hepatic or renal failure rats, cellular distribution in rat liver, and placental and milk transfer in rat were investigated"><entity charOffset="42-46" id="DDI-PubMed.19856794.s3.e0" text="L-AMB" /></sentence><sentence text=" Furthermore, to predict the drug-drug interaction, in vitro metabolism of amphotericin B (AMB) by rat, dog and human liver S9 fraction, and effects of L-AMB on drug-metabolizing enzyme systems were investigated"><entity charOffset="75-89" id="DDI-PubMed.19856794.s4.e0" text="amphotericin B" /><entity charOffset="91-94" id="DDI-PubMed.19856794.s4.e1" text="AMB" /><entity charOffset="152-154" id="DDI-PubMed.19856794.s4.e2" text="L-AMB" /><entity charOffset="154-156" id="DDI-PubMed.19856794.s4.e3" text="AMB" /><pair ddi="false" e1="DDI-PubMed.19856794.s4.e0" e2="DDI-PubMed.19856794.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19856794.s4.e0" e2="DDI-PubMed.19856794.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19856794.s4.e0" e2="DDI-PubMed.19856794.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19856794.s4.e0" e2="DDI-PubMed.19856794.s4.e3" /><pair ddi="false" e1="DDI-PubMed.19856794.s4.e1" e2="DDI-PubMed.19856794.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19856794.s4.e1" e2="DDI-PubMed.19856794.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19856794.s4.e1" e2="DDI-PubMed.19856794.s4.e3" /><pair ddi="false" e1="DDI-PubMed.19856794.s4.e2" e2="DDI-PubMed.19856794.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19856794.s4.e2" e2="DDI-PubMed.19856794.s4.e3" /></sentence><sentence text=" L-AMB was found to exist stably as a liposomal form in rat plasma without any notable transfer to milk or fetus in rats"><entity charOffset="1-3" id="DDI-PubMed.19856794.s5.e0" text="L-AMB" /><entity charOffset="3-5" id="DDI-PubMed.19856794.s5.e1" text="AMB" /><pair ddi="false" e1="DDI-PubMed.19856794.s5.e0" e2="DDI-PubMed.19856794.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19856794.s5.e0" e2="DDI-PubMed.19856794.s5.e1" /></sentence><sentence text=" After administration to hepatic failure rats, the CLtot of AMB decreased to 1/4 and the Vdss decreased to 1/8 compared with the control rat case"><entity charOffset="60-62" id="DDI-PubMed.19856794.s6.e0" text="AMB" /></sentence><sentence text=" In contrast, after administration to renal failure rats, plasma AUC of AMB did not significantly change compared with sham-operated rats"><entity charOffset="72-74" id="DDI-PubMed.19856794.s7.e0" text="AMB" /></sentence><sentence text=" These data suggest that hepatic clearance is the main determinant of the CLtot for L-AMB"><entity charOffset="84-86" id="DDI-PubMed.19856794.s8.e0" text="L-AMB" /><entity charOffset="86-88" id="DDI-PubMed.19856794.s8.e1" text="AMB" /><pair ddi="false" e1="DDI-PubMed.19856794.s8.e0" e2="DDI-PubMed.19856794.s8.e0" /><pair ddi="false" e1="DDI-PubMed.19856794.s8.e0" e2="DDI-PubMed.19856794.s8.e1" /></sentence><sentence text=" In rat liver, L-AMB was distributed mainly to non-parenchymal cells"><entity charOffset="15-17" id="DDI-PubMed.19856794.s9.e0" text="L-AMB" /><entity charOffset="17-19" id="DDI-PubMed.19856794.s9.e1" text="AMB" /><pair ddi="false" e1="DDI-PubMed.19856794.s9.e0" e2="DDI-PubMed.19856794.s9.e0" /><pair ddi="false" e1="DDI-PubMed.19856794.s9.e0" e2="DDI-PubMed.19856794.s9.e1" /></sentence><sentence text=" In the in vitro metabolism study using liver S9 fraction, no metabolite peaks were observed" /><sentence text=" After repeated administration of L-AMB to rats, there was no change in parameters related to the drug-metabolising enzyme system in liver microsomes"><entity charOffset="34-36" id="DDI-PubMed.19856794.s11.e0" text="L-AMB" /><entity charOffset="36-38" id="DDI-PubMed.19856794.s11.e1" text="AMB" /><pair ddi="false" e1="DDI-PubMed.19856794.s11.e0" e2="DDI-PubMed.19856794.s11.e0" /><pair ddi="false" e1="DDI-PubMed.19856794.s11.e0" e2="DDI-PubMed.19856794.s11.e1" /></sentence><sentence text=" These data demonstrate that clinically significant metabolism-based drug interaction with L-AMB should be less likely"><entity charOffset="91-93" id="DDI-PubMed.19856794.s12.e0" text="L-AMB" /><entity charOffset="93-95" id="DDI-PubMed.19856794.s12.e1" text="AMB" /><pair ddi="false" e1="DDI-PubMed.19856794.s12.e0" e2="DDI-PubMed.19856794.s12.e0" /><pair ddi="false" e1="DDI-PubMed.19856794.s12.e0" e2="DDI-PubMed.19856794.s12.e1" /></sentence><sentence text="" /></document>